LYNGE, DENMARK – WS Audiology (WSA) announced results for the first quarter of the financial year 2024/25 in line with expectations (October 1, 2024 – December 31, 2024).
“With an organic revenue growth of 4%, we are off to a good start of the financial year on a high comparative base from last year. Growth continues to be driven by solid performances across all regions and channels, based on our two strong and complementary brand platforms Signia and Widex. We look forward to launching new advanced hearing solutions on both platforms in the coming months, reaffirming our commitment to improving hearing care for all and simplifying the customer journey”
–Jan Makela, CEO of WSA
Q1 FY 2024/2025 highlights(Q1 last financial year in brackets)
WSA reported 4% organic revenue growth in Q1 FY 2024/2025, reaching EUR 670 million, in line with expectations. Growth was driven by strong performance across regions and channels, supported by its Signia and Widex brand platforms.
Highlights
- Steady Revenue Growth: 4% organic growth across all three regions (Americas, EMEA, APAC), maintaining momentum from previous quarters.
- Signia IX Platform Continues to Drive Growth: Last year’s Q1 revenue (13% growth)1 was boosted by the successful launch of Signia IX, which remains a key contributor across markets due to its advanced speech enhancement technology.
- Strong Online Performance: The online segment continued its high growth trajectory from previous quarters.
- Stable Profitability: EBITDA2 reached EUR 114 million, with a margin of 17.0% (vs. 16.4% last year), aligning with expectations.
- Leadership Updates: Marianne Vinding Ovesen joined as Chief Operating Officer, bringing expertise from Danaher Corporation, Radiometer, and Coloplast. Carsten Buhl, Regional President for WSA Americas, joined the Executive Board, emphasizing the Americas’ role in future growth alongside CEO Jan Makela and CFO Marianne Wiinholt.
Financial year 2024/25 outlook
Jan Makela, CEO
Outlook for the financial year 2024/25 is maintained at 3-6% organic revenue growth supported by our competitive product portfolio and upcoming launches.
The EBITDA margin before special items is expected to increase by 1-2%-points supported by our profitable growth program to drive future margin improvements.
References:
- Jensen NS, Wilson C, Kamkar Parsi H, Samra B, Hain J, Best S & Taylor B. 2024. Signia IX delivers more than twice the speech enhancement benefit in a noisy group conversation than the closest competitors. Signia White Paper.
- Measured as EBITDA before special items and net of R&D Capex.
About WS Audiology
Formed in 2019, through the merger of Sivantos and Widex, WS Audiology combines over 140 years’ experience in pioneering the use of technology to help people with hearing loss hear the sounds that make life wonderful. With truly differentiated brands like Widex, Signia, Rexton, Audio Service and Vibe, and with diverse assets across wholesale, retail, online, managed care and diagnostic solutions, we are active in over 130 markets. WS Audiology employs 12,500+ people and is privately owned by the Tøpholm and Westermann families and the Lundbeck Foundation, as well as funds under the management of EQT. As a global leader, our ambition is to unlock human potential by making wonderful sound part of everyone’s life.
Source: WSA
